Fig. 2: Combination approach. | Cell Death Discovery

Fig. 2: Combination approach.

From: CDK inhibitors promote neuroblastoma cell differentiation and increase sensitivity to retinoic acid—a promising combination strategy for therapeutic intervention

Fig. 2

A Two treatment settings were tested on NB cells (LAN-1, CHLA-90, and CHLA-172): CDKi followed by RA and the other way around. Metabolic activity after treatment was quantified by normalization to control. Mean + SD; n = 3 biological replicates. Two-way ANOVA (Tukey’s multiple comparisons test). #p < 0.05; ##p < 0.01; ###p < 0.001; ####p < 0.0001 vs. RA monotherapy. B Bliss independence calculation. CI < 1 synergistic; CI = 1 additive; CI > 1 antagonistic. C 3D-spheroid viability assessment using 3D-Glo assay. Individual values of single spheroids are shown, including the median; n = 3 biological replicates. One-way ANOVA (Tukey’s multiple comparisons test). #p < 0.05; ##p < 0.01; vs. monotherapy. A–C Doses: RA (all cell lines): 1.5 µM; LAN-1 abemaciclib: 0.2 µM; dinaciclib (all cell lines): 10 nM; fadraciclib: 0.4 µM; CHLA-90/CHLA-172: abemaciclib: 1.0 µM: fadraciclib: 1 µM.

Back to article page